Supporting the delivery of RECOVERY
Introduction to the RECOVERY trial at NUH
The RECOVERY trial
This national clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19.
A range of potential treatments have been suggested for COVID-19 but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive. The RECOVERY trial is currently testing some of these suggested treatments:
- Low-dose Dexamethasone (now only recruiting children)
- Azithromycin (a commonly used antibiotic)
- Tocilizumab (an anti-inflammatory treatment given by injection)
- Convalescent plasma (collected from donors who have recovered from COVID-19 and contains antibodies against the SARS-CoV-2 virus)
- REGN-COV2 (a combination of monoclonal antibodies directed against coronavirus).